Beijing Aosaikang Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
Beijing Aosaikang Pharmaceutical's earnings have been declining at an average annual rate of -54.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 24% per year. Beijing Aosaikang Pharmaceutical's return on equity is 1.2%, and it has net margins of 5.2%.
Key information
-54.4%
Earnings growth rate
-55.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -24.0% |
| Return on equity | 1.2% |
| Net Margin | 5.2% |
| Next Earnings Update | 31 Oct 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Beijing Aosaikang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,654 | 86 | 1,064 | 307 |
| 31 Mar 24 | 1,553 | -48 | 1,008 | 413 |
| 31 Dec 23 | 1,443 | -149 | 969 | 472 |
| 30 Sep 23 | 1,486 | -342 | 1,011 | 614 |
| 30 Jun 23 | 1,574 | -397 | 1,109 | 668 |
| 31 Mar 23 | 1,676 | -314 | 1,202 | 619 |
| 01 Jan 23 | 1,873 | -226 | 1,326 | 589 |
| 30 Sep 22 | 2,169 | -80 | 1,634 | 469 |
| 30 Jun 22 | 2,443 | 129 | 1,767 | 358 |
| 31 Mar 22 | 2,711 | 221 | 1,928 | 336 |
| 01 Jan 22 | 3,107 | 380 | 2,154 | 324 |
| 30 Sep 21 | 3,513 | 634 | 2,271 | 333 |
| 30 Jun 21 | 3,954 | 757 | 2,534 | 332 |
| 31 Mar 21 | 4,005 | 793 | 2,553 | 288 |
| 31 Dec 20 | 3,783 | 722 | 2,431 | 256 |
| 30 Sep 20 | 3,697 | 674 | 2,327 | 279 |
| 30 Jun 20 | 3,720 | 627 | 2,395 | 287 |
| 31 Mar 20 | 4,114 | 699 | 2,695 | 295 |
| 31 Dec 19 | 4,519 | 781 | 2,971 | 310 |
| 30 Sep 19 | 4,507 | 773 | 3,017 | 290 |
| 30 Jun 19 | 4,279 | 729 | 2,853 | 285 |
| 31 Mar 19 | 4,068 | 699 | 2,674 | 298 |
| 31 Dec 18 | 3,932 | 670 | 2,587 | 290 |
| 31 Dec 17 | 3,405 | 608 | 2,221 | 227 |
| 31 Dec 16 | 3,092 | 630 | 1,937 | 178 |
| 31 Dec 15 | 3,011 | 509 | 2,030 | 163 |
Quality Earnings: 002755 has a large one-off gain of CN¥80.9M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 002755 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002755's earnings have declined by 54.4% per year over the past 5 years.
Accelerating Growth: 002755 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 002755 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.6%).
Return on Equity
High ROE: 002755's Return on Equity (1.2%) is considered low.